These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 21416059)

  • 21. Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid.
    Bieliauskas AV; Weerasinghe SV; Negmeldin AT; Pflum MK
    Arch Pharm (Weinheim); 2016 May; 349(5):373-82. PubMed ID: 27062198
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histone deacetylase inhibitors in hematological malignancies and solid tumors.
    Chun P
    Arch Pharm Res; 2015 Jun; 38(6):933-49. PubMed ID: 25653088
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors.
    Frew AJ; Johnstone RW; Bolden JE
    Cancer Lett; 2009 Aug; 280(2):125-33. PubMed ID: 19359091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histone deacetylase inhibitors inducing human cervical cancer cell apoptosis by decreasing DNA-methyltransferase 3B.
    Liu N; Zhao LJ; Li XP; Wang JL; Chai GL; Wei LH
    Chin Med J (Engl); 2012 Sep; 125(18):3273-8. PubMed ID: 22964322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Histone deacetylase inhibitors in programmed cell death and cancer therapy.
    Marks PA; Jiang X
    Cell Cycle; 2005 Apr; 4(4):549-51. PubMed ID: 15738652
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents.
    Tan J; Cang S; Ma Y; Petrillo RL; Liu D
    J Hematol Oncol; 2010 Feb; 3():5. PubMed ID: 20132536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.
    Santini V; Gozzini A; Ferrari G
    Curr Drug Metab; 2007 May; 8(4):383-93. PubMed ID: 17504226
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer Epigenetics: Mechanisms and Crosstalk of a HDAC Inhibitor, Vorinostat.
    Lee J; R SH
    Chemotherapy (Los Angel); 2013 Jun; 2(111):. PubMed ID: 25243102
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
    Negmeldin AT; Pflum MKH
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells.
    Tabe Y; Konopleva M; Contractor R; Munsell M; Schober WD; Jin L; Tsutsumi-Ishii Y; Nagaoka I; Igari J; Andreeff M
    Blood; 2006 Feb; 107(4):1546-54. PubMed ID: 16223781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In situ exploring Chidamide, a histone deacetylase inhibitor, induces molecular changes of leukemic T-lymphocyte apoptosis using Raman spectroscopy.
    Xie Y; Tang P; Xing X; Zhao Y; Cao S; Liu S; Lu X; Zhong L
    Spectrochim Acta A Mol Biomol Spectrosc; 2020 Nov; 241():118669. PubMed ID: 32653824
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of histone deacetylase inhibitors for cancer treatment.
    Marchion D; Münster P
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Zinc-dependent Deacetylase (HDAC) Inhibitors with Different Zinc Binding Groups.
    Li Y; Wang F; Chen X; Wang J; Zhao Y; Li Y; He B
    Curr Top Med Chem; 2019; 19(3):223-241. PubMed ID: 30674261
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histone Deacetylase Inhibitors Romidepsin and Vorinostat Promote Hepatitis B Virus Replication by Inducing Cell Cycle Arrest.
    Yang Y; Yan Y; Chen Z; Hu J; Wang K; Tang N; Li X; Zhou Z
    J Clin Transl Hepatol; 2021 Apr; 9(2):160-168. PubMed ID: 34007797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in cardiac Nav1.5 expression, function, and acetylation by pan-histone deacetylase inhibitors.
    Xu Q; Patel D; Zhang X; Veenstra RD
    Am J Physiol Heart Circ Physiol; 2016 Nov; 311(5):H1139-H1149. PubMed ID: 27638876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
    Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
    Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
    [TBL] [Abstract][Full Text] [Related]  

  • 37. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance.
    Piekarz RL; Robey RW; Zhan Z; Kayastha G; Sayah A; Abdeldaim AH; Torrico S; Bates SE
    Blood; 2004 Jun; 103(12):4636-43. PubMed ID: 14996704
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy.
    Ramaiah MJ; Tangutur AD; Manyam RR
    Life Sci; 2021 Jul; 277():119504. PubMed ID: 33872660
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanisms of resistance to histone deacetylase inhibitors.
    Lee JH; Choy ML; Marks PA
    Adv Cancer Res; 2012; 116():39-86. PubMed ID: 23088868
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Epigenetic mechanisms and alcohol use disorders: a potential therapeutic target].
    Legastelois R; Jeanblanc J; Vilpoux C; Bourguet E; Naassila M
    Biol Aujourdhui; 2017; 211(1):83-91. PubMed ID: 28682229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.